Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499194 | 0.88 | ABCB1 (0.52) | MAOBARABCB1ALDH1A1LMNA | |
| SCHEMBL498756 | 0.83 | MAPT (0.50) | MAOBMAOAARALDH1A1LMNA | |
| SCHEMBL29382056 | 0.83 | CYP1A1 (0.39) | MAOBLMNAMAPTABCG2 | |
| SCHEMBL1933383 | 0.83 | CYP1A1 (0.39) | MAOBLMNAMAPTABCG2 | |
| SCHEMBL3962818 | 0.81 | MEN1 (0.43) | ARLMNAMAPT | |
| SCHEMBL3970021 | 0.81 | ABCB1 (0.43) | ARABCB1ALDH1A1LMNAMAPT | |
| SCHEMBL3964836 | 0.79 | ALDH1A1 (0.48) | MAOBMAOAALDH1A1LMNAMAPT | |
| SCHEMBL1935354 | 0.79 | CYP1A1 (0.53) | MAOB | |
| SCHEMBL29379151 | 0.79 | CYP1A1 (0.53) | MAOB | |
| SCHEMBL498651 | 0.78 | ABCB1 (0.47) | MAOBARABCB1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | KCNK3 4103/4885KCNK9 4514/4885MAOB 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.